Notice2024-08008
Medicare Program; Meeting Announcement for the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests, July 25-26, 2024
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 16, 2024
Issuing agencies
Health and Human Services DepartmentCenters for Medicare & Medicaid Services
Abstract
This notice announces the public meeting dates for the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests (the Panel) on Thursday, July 25, 2024 and Friday, July 26, 2024. The purpose of the Panel is to advise the Secretary of the Department of Health and Human Services and the Administrator of the Centers for Medicare & Medicaid Services on issues related to clinical diagnostic laboratory tests.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 74 (Tuesday, April 16, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 74 (Tuesday, April 16, 2024)]
[Notices]
[Pages 26893-26895]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-08008]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-1824-N]
Medicare Program; Meeting Announcement for the Medicare Advisory
Panel on Clinical Diagnostic Laboratory Tests, July 25-26, 2024
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces the public meeting dates for the
Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests (the
Panel) on Thursday, July 25, 2024 and Friday, July 26, 2024. The
purpose of the Panel is to advise the Secretary of the Department of
Health and Human Services and the Administrator of the Centers for
Medicare & Medicaid Services on issues related to clinical diagnostic
laboratory tests.
DATES:
Meeting Dates: The hybrid (in-person and virtual) meeting of the
Panel is scheduled for Thursday, July 25, 2024 from 10:00 a.m. to 4:00
p.m., Eastern Daylight Time (E.D.T.) and Friday, July 26, 2024, from
10:00 a.m. to 4:00 p.m., E.D.T. The Panel is also expected to
participate virtually in the Clinical Laboratory Fee Schedule (CLFS)
Annual Public Meeting for Calendar Year (CY) 2025 on Tuesday, June 25,
2024, to gather information and ask questions to presenters. Notice of
the CLFS Annual Public Meeting for CY 2025 is published elsewhere in
this issue of the Federal Register.
Deadline for Meeting Registration: All stand-by speakers for the
Panel meeting must register electronically to our CDLT Panel dedicated
email box, <a href="/cdn-cgi/l/email-protection#4201060e1612232c272e02212f316c2a2a316c252d34"><span class="__cf_email__" data-cfemail="91d2d5ddc5c1f0fff4fdd1f2fce2bff9f9e2bff6fee7">[email protected]</span></a> by June 1, 2024.
In-Person Attendance: If attending the meeting in person at the CMS
Headquarters, registration is required and must be completed by May 30,
2025. For more information on how to register as an in-person attendee,
see the ``Registration Instructions'' (section IV of this notice).
Virtual Attendee Only: The public may also view this meeting via
webinar or listen-only via teleconference. If attending the meeting via
webinar, or listen-only via teleconference, registration is not
required for non-speakers.
Webinar and Teleconference Meeting Information: Teleconference
dial-in instructions, and related webinar details will be posted on the
meeting agenda, which will be available on the CMS website
approximately 2 weeks prior to the meeting at <a href="https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html">https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html</a>. A preliminary
agenda is described in section II of this notice.
ADDRESSES: The Panel meeting will be held virtually and in-person at
the campus of the Centers for Medicare & Medicaid Services (CMS),
Central Building, 7500 Security Boulevard, Baltimore, Maryland 21244-
1850.
FOR FURTHER INFORMATION CONTACT: The CLFS Policy Team via email,
<a href="/cdn-cgi/l/email-protection#88cbccc4dcd8e9e6ede4c8ebe5fba6e0e0fba6efe7fe"><span class="__cf_email__" data-cfemail="c083848c9490a1aea5ac80a3adb3eea8a8b3eea7afb6">[email protected]</span></a>; or Rasheeda Arthur, (410) 786-3434. The CMS
Press Office, for press inquiries, (202) 690-6145.
SUPPLEMENTARY INFORMATION:
I. Background
The Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests
(CDLTs) (the Panel) is authorized by section 1834A(f)(1) of the Social
Security Act (the Act) (42 U.S.C. 1395m-1), as established by section
216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L.
113-93), enacted on April 1, 2014. The Panel is subject to the Federal
Advisory Committee Act (FACA), as amended (5 U.S.C. appendix 2), which
sets forth standards for the formation and use of advisory panels.
Section 1834A(f)(1) of the Act directs the Secretary of the
Department of Health and Human Services (the Secretary) to consult with
an expert outside advisory panel established by the Secretary, composed
of an appropriate selection of individuals with expertise in issues
related to clinical diagnostic laboratory tests, which may include the
development, validation, performance, and application of such tests.
Such individuals may include molecular pathologists, researchers, and
individuals with expertise in laboratory science or health economics.
The Panel will provide input and recommendations to the Secretary
and the Administrator of the Centers for
[[Page 26894]]
Medicare & Medicaid Services (CMS), on the following:
<bullet> The establishment of payment rates under section 1834A of
the Act for new clinical diagnostic laboratory tests, including whether
to use ``crosswalking'' or ``gap filling'' processes to determine
payment for a specific new test.
<bullet> The factors used in determining coverage and payment
processes for new clinical diagnostic laboratory tests.
<bullet> Other aspects of the payment system under section 1834A of
the Act.
A notice announcing the establishment of the Panel and soliciting
nominations for members was published in the October 27, 2014 Federal
Register (79 FR 63919 through 63920). In the August 7, 2015 Federal
Register (80 FR 47491), we announced membership appointments to the
Panel along with the first public meeting date for the Panel, which was
held on August 26, 2015. Subsequent meetings of the Panel and
membership appointments were also announced in the Federal Register.
II. Agenda
The Agenda for the July 25 and July 26, 2024 hybrid Panel meeting
will provide for discussion and comment on the following topics as
designated in the Panel's charter:
<bullet> Calendar Year (CY) 2025 Clinical Laboratory Fee Schedule
(CLFS) new and reconsidered test codes, which will be posted on the CMS
website at <a href="https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Laboratory_Public_Meetings.html">https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Laboratory_Public_Meetings.html</a>.
<bullet> Other CY 2025 CLFS issues designated in the Panel's
charter and further described on our Agenda.
A detailed Agenda will be posted approximately 2 weeks before the
meeting, on the CMS website at <a href="https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/clfs-advisory-panel">https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/clfs-advisory-panel</a>. The Panel will make recommendations to the Secretary and the
Administrator of CMS regarding crosswalking and gap filling for new and
reconsidered laboratory tests discussed during the CLFS Annual Public
Meeting for CY 2025. The Panel will also provide input on other CY 2025
CLFS issues that are designated in the Panel's charter and specified on
the meeting agenda.
III. Meeting Participation
This meeting is open to the public. Stand-by speakers may
participate in the meeting in-person via teleconference and webinar. A
stand-by speaker is an individual who will speak on behalf of a company
or organization if the Panel has any questions during the meeting about
technical information described in the public comments or presentation
previously submitted or presented by the organization or company at the
recent CLFS Annual Public Meeting for CY 2025 on June 25, 2024. The
public may also attend the hybrid meeting in-person or view and/or
listen-only to the meeting via teleconference and webinar.
IV. Registration Instructions
Beginning May 1, 2024 and ending May 30, 2024 at 5:00 p.m. E.D.T.,
registration for stand-by speakers and in-person attendees may be
completed by sending an email to the following resource box:
<a href="/cdn-cgi/l/email-protection#6023242c3430010e050c20030d134e0808134e070f16"><span class="__cf_email__" data-cfemail="145750584044757a7178547779673a7c7c673a737b62">[email protected]</span></a>.
If you are registering (for example, stand-by speaker or in-person
attendee), the subject of the email should state ``Registration for
CDLT Panel Meeting.'' Note: No registration is required for
participants who plan to view the Panel meeting via webinar or listen
via teleconference.
In the email, all of the following information must be submitted
when registering:
<bullet> Name.
<bullet> Indicate if you are registering as a ``Stand-by speaker''
or ``In-Person Attendee.''
<bullet> Organization or company name.
<bullet> Email addresses that will be used by the speaker in order
to connect to the virtual meeting.
<bullet> New or Reconsidered Code(s) for which the company or
organization you are representing submitted a comment or presentation,
if applicable.
Registration details may not be revised once they are submitted. If
registration details require changes, a new registration entry must be
submitted by the date specified in the DATES section of this notice.
Additionally, registration information must reflect individual-level
content and not reflect an organization name. Also, we request
organizations register all individuals at the same time. That is, one
individual may register multiple individuals at the same time.
After registering, a confirmation email will be sent upon receipt
of the registration. The email will provide information to the attendee
in preparation for the meeting. Registration is only required for
stand-by speakers and members of the public attending the meeting at
the CMS campus (address specified in the ADDRESSES section of this
notice). All registration must be submitted by the deadline specified
in the DATES section of this notice. We note that no registration is
required for participants who plan to view the Panel meeting via
webinar or listen via teleconference.
V. Panel Recommendations and Discussions
The Panel's recommendations will be posted approximately 2 weeks
after the meeting on the CMS website at <a href="https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html">https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html</a>.
VI. Security, Building, and Parking Guidelines
The hybrid meeting will be virtual and will be held in a Federal
Government building; therefore, Federal security measures are
applicable. In planning your arrival time, we recommend allowing
additional time to clear security. We suggest that you arrive at the
CMS campus and parking facilities between 9:00 a.m. and 10:00 a.m.
E.D.T., so that you will be able to arrive promptly at the meeting by
10:00 a.m. E.D.T. Individuals who are not registered in advance will
not be permitted to enter the building and will be unable to attend the
meeting. We note that the public may not enter the CMS building earlier
than 9:15 a.m. E.D.T. (45 minutes before the convening of the meeting).
<bullet> Presentation of government-issued photographic
identification to the Federal Protective Service or Guard Service
personnel. Persons without proper identification may be denied access
to the building.
<bullet> Interior and exterior inspection of vehicles (this
includes engine and trunk inspection) at the entrance to the grounds.
Parking permits and instructions will be issued after the vehicle
inspection.
<bullet> Passing through a metal detector and inspection of items
brought into the building. We note that all items brought to CMS,
whether personal or for the purpose of demonstration or to support a
demonstration, are subject to inspection. We cannot assume
responsibility for coordinating the receipt, transfer, transport,
storage, set-up, safety, or timely arrival of any personal belongings
or items used for demonstration or to support a demonstration.
VII. Special Accommodations
Individuals attending, viewing, or listening to the meeting who are
hearing or visually impaired and have special requirements, or a
condition that requires special assistance, should send an email to the
resource box (<a href="/cdn-cgi/l/email-protection#d794939b8387b6b9b2bb97b4baa4f9bfbfa4f9b0b8a1"><span class="__cf_email__" data-cfemail="3c7f7870686c5d5259507c5f514f1254544f125b534a">[email protected]</span></a>). The
[[Page 26895]]
deadline for submitting this request is listed in the DATES section of
this notice.
VIII. Copies of the Charter
The Secretary's Charter for the Medicare Advisory Panel on CDLT's
is available on the CMS website at <a href="https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/clfs-advisory-panel">https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/clfs-advisory-panel</a> or you may obtain a copy of the charter by submitting a
request to the contact listed in the FOR FURTHER INFORMATION CONTACT
section of this notice.
IX. Collection of Information Requirements
This document does not impose information collection requirements,
that is, reporting, recordkeeping, or third-party disclosure
requirements. Consequently, there is no need for review by the Office
of Management and Budget under the authority of the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501 et seq.).
The Administrator of CMS, Chiquita Brooks-LaSure, having reviewed
and approved this document, authorizes Vanessa Garcia, who is the
Federal Register Liaison, to electronically sign this document for
purposes of publication in the Federal Register.
Vanessa Garcia,
Federal Register Liaison, Centers for Medicare & Medicaid Services.
[FR Doc. 2024-08008 Filed 4-15-24; 8:45 am]
BILLING CODE 4120-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 16, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.